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THE COST OF PREVENTING INFLUENZA PANDEMIC: MEXICAN 
ELDERLY POPULATION SCENARIO
Soria-Cedillo IF1, Baca-Muro VI2, Alejandro P3, Garcia-Contreras F4
1Research Consulting, Hacienda Ojo de Agua, Mexico, 2Research Consulting, Puebla, Mexico, 
3Novartis Farmaceutica Mexico, Mexico City, Mexico City, Mexico, 4Instituto Mexicano de 
Seguro Social, Mexico D.F., Mexico
OBJECTIVES: To compare the budget impact in the main Public Health Institution 
in Mexico due to the use of MF59-adjuvanted vaccine (MF59), split vaccine (SPL) 
and a No Vaccination Program Alternative (NOVA) in Mexican elderly population. 
METHODS: A budget impact analysis considering a public health institution perspec-
tive was performed. The expenses of the Mexican Health Care System due to a vacci-
nation program (vaccines, vaccination program, medical visits, treatment of inﬂuenza 
and inﬂuenza related complications, hospitalization and intensive care unit cost) were 
simulated with MF59 or SPL versus NOVA in elderly population affected by an 
inﬂuenza pandemic. A case scenario of high incidence inﬂuenza (5% of population) 
with three sub-scenarios was designed: a) 20%, b) 30%, and c) 50% of patients 
developing complications related to inﬂuenza. A systematic literature review was 
designed in order to include the most recent information about vaccines effectiveness 
measured as the ability of provide seroprotection against Inﬂuenza A/H1N1 strain and 
pandemic historical inﬂuenza incidences recommended by World Health Organiza-
tion. Use of resources and cost matrixes were designed with the most recent data of 
main Public Health Institution in Mexico, which attends about ﬁfty percent of the 
total population in Mexico. RESULTS: The cost of treatment of inﬂuenza and com-
plications related to inﬂuenza were estimated in US$38.84 and US$5,052.06, res-
pectively. Simulating prevention of inﬂuenza pandemic affecting 5% of Mexican 
elderly population results in less expenses for Public Health Institutions when 
MF59 is used in vaccination program compared to SPL and NOVA without varying 
the proportion of patients getting complications related to inﬂuenza (20%: MF59-
US$69,833,474.83; SPL-US$84,692,366.64; NOVA-US$236,082,644.63. 30%: 
MF59-US$84,610,768.22; SPL-US$117,657,098.05; NOVA-US$349,754,132.23. 50%: 
MF59-US$113,903,164.91; SPL-US$183,586,560.86; NOVA-US$577,097,107.44). 
CONCLUSIONS: Using an MF59-adjuvanted vaccine as a preventive alternative in 
an Inﬂuenza Pandemic affecting elderly population in Mexico, represents important 
savings for Mexican Public Health Institutions compared to SPL and NOVA.
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A BUDGET IMPACT MODEL TO ESTIMATE THE ECONOMIC IMPACT OF 
ITRACONAZOLE IN PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS 
IN PATIENTS WITH NEUTROPENIA IN SPAIN
Darba J1, Restovic G2
1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics & Outcomes Research 
SL, Barcelona, Spain
OBJECTIVES: A budget impact model (BIM) was developed to estimate the economic 
impact of intraconazole in prophylaxis of invasive fungal infections (IFI) in patients 
with neutropenia in Spain. METHODS: A BIM was developed using published data 
for disease prevalence, population growth, pharmaceutical ex-factory prices, health 
care resource consumption and market shares forecasting for Spain. This study was 
developed under the perspective of the health care system and time horizon considered 
was 5 years with an annual discount rate of 3%. According to a panel of clinical 
experts, drugs considered in this study were all different “azoles” currently used in 
prophylaxis in Spain regardless whether they have been authorized for this purpose 
or not. These are the following ones: itraconazole, posaconazole, ﬂuconazole and 
voriconazole. This model estimated the cost of this disease for the Spanish health care 
system with and without the partial replacement (from 5% to 15%) of posaconazale 
by itraconazole. All costs were referred to year 2009. RESULTS: According to ofﬁcial 
statistic, target population with hematologic cancers in prophylaxis of IFI in Spain 
would be around 70,000 patients in the ﬁrst year, arriving at 75,000 in the 5th year. 
Direct medical costs for the next 5 years were estimated at a1424 million before the 
replacement of posaconazole by itraconazole. Costs were estimated at a1423 million 
whether this replacement would take place. CONCLUSIONS: The replacement of 
posaconazale by itraconazole in a very low percentage (from 5% to 15%) would 
represent a savings of a830,000 for the Spanish health care system in the next 5 
years.
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BUDGET IMPACT ANALYSIS OF NEW ANTRIRETROVIRAL MEDICINES 
FOR TREATMENT OF HIV PATIENTS IN BULGARIA
Dimitrova MJ, Stefanova MT, Petrova GI
Medical University Soﬁa, Faculty of Pharmacy, Soﬁa, Bulgaria
OBJECTIVES: To analyze the budget impact of two newly registered for Bulgaria 
antiretroviral medicines tenofovir and emtricitabine for treatment of HIV infection. 
The point of view is that of health care system and time horizon is one year. 
METHODS: Budget impact model was created for antiretroviral medicinal therapies 
for ﬁrst and second line treatment. Two scenarios were analyzed for highly active 
antiretroviral therapy (HAART) including 12 medicines combinations for ﬁrst line and 
7 combinations for second line therapy. Health care resources included in the model 
are medicines, physician consultation ﬁrst and 11 follow up attendances, 12 clinical, 
3 virology and 6 immunology tests. In the model was varied the cost of the medicines 
therapy and number of patients. RESULTS: Untill June 2009 in Bulgaria are registered 
991 HIV positive patients and near 230 of them are on highly active antiretroviral 
therapy (HAART)—ﬁrst or second line depending on their virology status. Preliminary 
results from the budget impact model show that in the ﬁrst scenario (ﬁrst line therapy) 
the combination tenofovir—emtricitabine—efavirenz is cost saving to the health care 
system compared to three of the most effective HAART regimens: AZT/3TC- LPV/r, 
3TC/ABC- SQV and TDF-3TC-EFV and saves 141 981,46 Euro, 83461,53 Euro and 
a2445.99, respectively for one year. The second scenario (second line therapy) is 
indicated only for certain patients according to their virology status. In this scenario 
the regimen TDF-FTC-EFV is cost saving to the health care system in comparison with 
TDF-3TC-EFV and saves a2445.99. CONCLUSIONS: TDF-FTC-EFV is cost saving 
for the health care system compared to three of the most effective regimens in Bulgaria. 
The combination is much appropriate as ﬁrst line HAART.
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BUDGET IMPACT ANALYSIS OF THREE CANDINS IN THE TREATMENT 
OF INVASIVE CANDIDIASIS IN ADULT NON- NEUTROPENIC PATIENTS 
IN SPAIN
García M, Martí B, Ferro B
Health Outcomes Research, Pﬁzer, Spain
OBJECTIVES: Three candins had been approved for the treatment of invasive candi-
diasis (IC). Different drugs are associated with different needs for dose adjustment 
which might affect the total cost. The aim of this study was to estimate the budget 
impact of caspofungin, micafungin and anidulafungin in the treatment of 100 patients 
with invasive candidiasis from the perspective of the Spanish hospital pharmacy 
setting. METHODS: Possible scenarios varying percentage of doses adjustment 
required were also considered to assess the global impact on costs. Prices for each 
presentation were obtained from the Spanish database “portalfarma”, expressed in 
a2008. Only drug acquisition costs were considered into the analysis. Total cost for 
the three candins was ﬁnally displayed. RESULTS: Cost per episode associated with 
the use of anidulafungin remained constant at a6000. When considering caspofungin, 
cost-per-episode varies from a4665 to a7991 depending on the patient’s weight and 
hepatic dysfunction. Finally micafungin total cost-per-episode was estimated at a6,000 
when low doses where required while higher doses based on inadequate respond had 
a cost of a10,714 per IC episode. Total cost based on a hypothetic cohort of 100 
patients with IC treated with anidulafungin would be of a600,000, while the cost of 
caspofungin and micafungin on the base case will be a637,084 and a632,998, respec-
tively, depending on dose adjustment required. CONCLUSIONS: Patients treated with 
Anidulafungin did not required dose adjustment unlike caspofungin and micafungin. 
The use of anidulafungin in the treatment of adult non-neutropenic patients with 
invasive candidiasis is a cost saving treatment option that allows a better control of 
antifungal budget based on a lower total cost per episode, from the pharmacy depart-
ment perspective in Spain.
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BUDGET IMPACT MODEL: LEVOFLOXACIN VS STANDARD THERAPIES 
IN THE TREATMENT OF INPATIENT CAP
Pitrelli A1, Bamﬁ F1, Pippo L2
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OBJECTIVES: To develop a Budget Impact Model (BIM) to estimate the ﬁnancial 
consequences of the use of levoﬂoxacin for the treatment of community-acquired 
pneumonia (CAP) in Italian Hospitals to support health decision makers. METHODS: 
We developed a BIM for levoﬂoxacin that compares current treatments for CAP, their 
efﬁcacy and safety and the resource use and costs as apply to the population of interest. 
Several dimensions were considered: drug consumption, frequency and days of treat-
ment, health care professional costs, disposable (material), hospitalization costs and 
need of a second line treatment. Different scenarios in antibiotic treatment of CAP 
were included for comparison, such as i.v. therapy or switch therapy and levoxacin 
is compared to current alternative in monotherapy and in combination therapy. 
RESULTS: CAP is an infection still associated to considerable rates of morbidity and 
mortality and with important consequences from the social and economic perpspec-
tive. In Italy the annual incidence of hospitalization due to CAP is about 3 cases every 
1000 habitants, with rather high mortality rates: from 15/100.000 cases of the 
national mean to 70/100.000 cases for subjects older than 65 years. More than 90% 
of CAP costs are associated to hospitalizations (500 million euro. The model we 
developed results in an interactive tool that allows users (payers) to understand the 
relation between the characteristics of their scenario and the possible budget conse-
quences of the different treatment choices and informs them about the most affordable 
option among current treatments for CAP (including levoﬂoxacin) according to the 
features of their own scenario CONCLUSIONS: BIMs are primarily intended to     
inform health care decision makers, especially those who are responsible for national, 
regional, or local health care budgets. For this reason methodology and results were 
reviewed in an external engagement with payers to validate the model in a real 
scenario.
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BUDGET IMPACT OF HIV POST-EXPOSURE PROPHYLAXIS:  
AN EXAMPLE OF HOSPITAL POINT OF VIEW AFTER NEW 
RECOMMENDATIONS IN FRANCE
Bernard M, Askin D, Massias L, Arnaud P
Bichat-Claude Bernard hospital, Paris, Ile de france, France
OBJECTIVES: Bichat-Claude Bernard hospital (BCB) is one of the reference centers 
in HIV care in Paris (France) and has established procedures for post-exposure pro-
phylaxis (PEP). Only patients at high risk of contamination received antiretroviral 
(ARV) treatment. The aim of this study was to describe the use of PEP (occupational 
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or not), and to estimate the impact of treatment cost. METHODS: We conducted a 
population-based observational cohort study of patients who presented for PEP in 
BCB in 2007 and 2008. Data collected included details of HIV exposure, drug regi-
mens and treatment cost. RESULTS: In 2008, 498 patients came in emergencies for 
a possible HIV exposure (17% more than 2007). The majority were male (61.4%) 
and presented after sexual exposure (60.6%). Mean age was 31.4/0.4 years. Only 
in 47.6%, ARVs were prescribed (tri-therapy in all cases) according to guidelines. 
Median time to receive PEP after hospital admission was 1h07. On average, 19/1 
days of treatment were dispensed per patient. For 2008, the total acquisition cost of 
PEP drugs was a13,8580 (1.1% of the total HIV treatment budget, 14.6% compared 
to 2007) equivalent of a171,785 in a societal point of view. Mean cost per patient 
was a585/38. Without discriminating prescription of PEP, the total cost would have 
been a291,243. Since French recommendations (march 2008) authorizing TDFFTC 
(Truvada®) in ﬁrst intention as AZT3TC (Combivir®), associated with lopinavir/r, 
we observed a change in PEP prescription compared to 2007, which explained at 
72.5% the cost’s increase observed. CONCLUSIONS: The review of cost-effectiveness 
suggests that PEP may be cost-effective only in certain population subgroups. In our 
hospital only targeted patients at high-risk received PEP according to guidelines. The 
cost difference between TDFFTC and AZT3TC highlighted here will enable us to 
begin a revision of local recommendations.
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THE ECONOMIC IMPLICATION OF A RAPID DIAGNOSE AND EARLY 
SHIFT IN THERAPY IN PATIENTS WITH INVASIVE CANDIDA 
INFECTION
Kolbye A1, Clausen SR1, Schierbeck J2, Andersen JS3
1Pﬁzer Denmark, Ballerup, Denmark, 2Odense University Hospital, Odense C, Denmark, 
3Copenhagen University Hospital, Copenhagen E, Denmark
Patients at risk of developing invasive candida infection can be diagnosed early, using 
new rapid technologies. Accelerated diagnose allows earlier shift in antifungal therapy 
for patients insufﬁciently treated by ﬁrst choice of antifungal medicine. OBJECTIVES: 
To analyze the economic consequences for the Intensive Care Units (ICU) of a faster 
diagnose and when indicated earlier shift in therapy using PCR compared with a tra-
ditional blood culture. METHODS: A decision-tree based costing model was designed 
to compare the two approaches to diagnosing (blood culture alone versus PCR plus 
blood culture). The model compares the costs of the diagnostic methods, costs of 
medicines as well as costs of LOS at the ICU for the two alternatives. The data for 
the costing model was based on data for a half year of patients at Copenhagen Uni-
versity Hospital in 2008 having an invasive candida infection (n  10), and all costs 
were from a Danish perspective. RESULTS: All patients in risk of developing invasive 
candida infection are treated with ﬂuconazol until diagnosed positive. Based on a 
national surveillance of patterns of resistance up to 35% of the patients will be shifted 
to an echinocandin after diagnose. A faster diagnose and early shift in therapy with 
echinocandin will imply in average an extra medicine costs between a 254–267. 
However, at the same time LOS at ICU will in average be reduced by 1.4 days, which 
will result in savings as high as a4859. Diagnose with PCR and use of echinocandin 
for the 35% of the relevant patients could therefore result in savings up to a4605 per 
patient. CONCLUSIONS: Rapid diagnose with PCR and early shift in therapy to 
echinocandin is cost-effective. However, different budgets (including the DRG 
payment) at the hospital are affected, why silo thinking might be a barrier, when 
deciding upon the cost-effective strategy.
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COST-EFFECTIVENESS OF HEPTAVALENT PNEUMOCOCCAL 
CONJUGATE VACCINE (PCV-7) IN MEXICO
Carlos F1, Mercado G2, Aguirre A2, Vargas A1, Bierschwale H2
1R A C Salud Consultores, SA de CV, Ciudad de Mexico, Distrito Federal, Mexico, 2Wyeth 
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OBJECTIVES: Streptococcus pneumoniae is one of the most frequent causes of 
invasive(IPD) and non-invasive infections(Non-IPD), causing 1.6 million deaths 
worldwide in 2002. PCV-7 provides a reliable protection for children a2 years old.
We aimed to perform an economic evaluation of three doses plus a booster (31) 
compared to an abbreviated scheme (21) and with non-vaccination. METHODS: We 
developed a Markov model of ten annual cycles to estimate the costs and outcomes 
for a birth cohort of 1,955,284. Another model was designed to estimate the herd 
immunity effects during a year in the non-vaccinated population,98% coverage rate 
was assumed.Efﬁcacy data from published sources was adjusted by serotype coverage 
and all costs reﬂect local practice.Direct medical costs included the immunization 
program, medical attention of IPD/Non-IPD and sequels of meningitis.All costs (dis-
counted with an annual rate of 5%) were calculated in 2008 Mexican Pesos (MXP) 
and then expressed in US dollars (USD) using an exchange rate of 1 USD to 11.14 
MXP (exchange rate by the time the study was performed). Disability-adjusted life 
years (DALY) were estimated following standard methods and assumptions. RESULTS: 
For the vaccinated cohort, the full scheme is a cost-saving intervention, costing US$10 
million less than the abbreviate scheme and US$51 million less than non-vaccination. 
Adding the herd immunity beneﬁts, overall savings increases to US$17.40 million 
(beneﬁt : cost ratio 1.08) compared to (21) scheme and reaches US$121.19 million 
(beneﬁt : cost ratio 1.54) compared with non-vaccination.The DALY averted with the 
full scheme are 35,988 and 172,813 compared to (21) scheme and non-vaccination, 
respectively. CONCLUSIONS: The full scheme (31) of PCV-7 had lower costs and 
better health outcomes when compared to both an abbreviated scheme (21) and 
non-vaccination, even if herd immunity is not taken into account.Although the 31 
schedule is dominant the 21 schedule remains highly cost effective vs. no vaccination 
at all.
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THE COST OF ROTAVIRUS GASTROENTERITIS IN YOUNG CHILDREN 
IN FOUR EUROPEAN COUNTRIES: A STUDY IN PRIMARY CARE
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OBJECTIVES: To investigate the resource use and cost of rotavirus gastroenteritis 
(RVGE) in children aged 5 years presenting to primary care in four European coun-
tries, Italy, Spain, the Czech Republic and Poland. METHODS: This observational, 
prospective study collected data from children aged 5 years presenting to primary 
care (general practitioners and paediatricians) with acute gastroenteritis (deﬁned as 
diarrhoea for 14 days) and a positive test for rotavirus. Severity of RVGE was 
assessed using the Vesikari score. Parents completed a cost questionnaire at a follow-
up visit or phone call 14 days after the episode, recording information on: direct 
medical costs (physician visits and contacts including the initial visit, use of medica-
tion, rehydration solutions and nutritional products); direct non-medical costs (trans-
port, supervision/carer costs, other costs); and indirect costs (days lost at work or 
school/daycare). All costs were recorded in 2006 Euros. RESULTS: Cost data were 
available for 502 children, of whom 126 were in Italy, 217 in Spain, 87 in Poland 
and 72 in the Czech Republic. A total of 65% of the children (n  326) were aged 0–24 
months, 52% (n  263) were male, and 82% (n  410) were rated as moderate/severe 
using the Vesikari score. The mean total societal cost per child was a170.6 in Italy, 
a169.7 in Spain, a44.0 in Poland and a37.6 in the Czech Republic. The share of the 
total societal cost borne by the family was highest in Italy (57.5%), compared with 
55.0% in Poland, 48.3% in Spain and 35.9% in the Czech Republic. CONCLU-
SIONS: Paediatric RVGE presenting to primary care is associated with substantial 
direct and indirect costs, a high proportion of which are borne by families. These data 
will be valuable in economic evaluations of paediatric rotavirus vaccination. Acknowl-
edgements to the SPRIK investigators, VIVA Spanish investigators, José Baldó, Nadia 
Meyer and Montse Soriano-Gabarró
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THE COST BURDEN OF ACUTE GASTROENTERITIS IN INFANTS AND 
YOUNG CHILDREN ATTENDING DAYCARE CENTRES IN FRANCE
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1Omega Research, Dublin 9, Ireland, 2Hopital Trousseau, Paris, France, 3GSK, Rixensart, 
Belgium
OBJECTIVES: To investigate the cost of acute gastroenteritis (AGE) in children aged 
3 years attending daycare centres in France. METHODS: This observational, pro-
spective study was conducted at 15 daycare centres in Paris, France. Children were 
eligible for the study if they had an episode of AGE (deﬁned as q3 loose stools within 
24 hours, lasting for 14 days) before their third birthday. Parents completed a cost 
questionnaire for the affected child and household contacts (a person spending at least 
50% of nights in the same home) who also experienced AGE in the 14 days before 
or after onset of gastroenteritis in the affected child. Information on direct medical 
costs (general practitioner or paediatrician visits and phone consultations, hospitalisa-
tions, emergency room visits, and use of medication, rehydration solutions and nutri-
tional products); direct non-medical costs (transport, supervision/carer costs, other 
costs); and indirect costs (lost workdays) was recorded in 2006 Euros. RESULTS: 
Cost data were available for 71 episodes in 62 subjects (57 children attending daycare 
and 5 household contacts) of the 113 subjects in the study. Of the children attending 
daycare, 47% were male and 86% were aged a24 months. Most episodes (67%) were 
scored as mild/moderate using the Vesikari scale and 21% tested positive for rotavirus. 
The mean societal cost was a253.6 (SD 409.3) per episode, of which direct medical 
costs accounted for a93.2 (37%), non-medical direct costs a16.0 (6%) and indirect 
costs a144.4 (57%). Most of the total cost (63%) was borne by families, reﬂecting 
the importance of indirect costs. Rotavirus-positive episodes (n  15) had higher mean 
total costs than rotavirus-negative episodes (n  51), at a437.7 (SD a527.1) and a172.0 
(SD a304.0) per episode, respectively. CONCLUSIONS: These data show the impor-
tance of indirect costs borne by families, and provide useful information for economic 
evaluations of paediatric rotavirus vaccination.
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TREATMENT COSTS FOR CHRONIC HEPATITIS B (CHB) IN URBAN 
CHINA
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OBJECTIVES: In China, 93 million people are chronically infected with hepatitis B 
virus, causing around 19,300 deaths annually. However, detailed costs of treating 
CHB have not been well studied, particularly within the growing urban areas. This 
study aimed to assess the annual direct medical costs for the management of CHB in 
three cities in China. METHODS: Medical claims of 8,954 urban CHB patients from 
Beijing, Nanjing, and Qingdao between January 2006 and December 2007 were ran-
domly reviewed. Demographics; inpatient and outpatient costs; type of medications, 
including antiviral and Traditional Chinese Medicine [TCM], were all recorded and 
